Prevalence and cumulative 5-year incidence of chronic lymphocytic leukemia in the adult population in the Russian Federation and Ukraine: Data from the LEUKOSPECT study

Abstract

Objectives: LEUKOSPECT was a retrospective, multicenter, epidemiologic study carried out in Russia and Ukraine, aiming to assess the prevalence and cumulative 5-year incidence of chronic lymphocytic leukemia (CLL) in the adult population.

Methods: All data were collected manually from patient medical records at each of the study sites and from official censuses. CLL prevalence and incidence were determined from a count of CLL cases (previously diagnosed and new cases) in the population who made at least one clinic visit for CLL during the period from 1 January 2009 to 31 December 2013.

Results: The recorded cumulative 5-year incidence of CLL during the study ranged from 1.46 per 100 000 persons (95% CI: 0.85–2.34) in Yekaterinburg, Russia, to 4.34 per 100 000 persons (95% CI: 2.48–7.04) in Luhansk, Ukraine. In 2013, the lowest prevalence of CLL was also recorded in Yekaterinburg: 7.11 per 100 000 persons (95% CI: 5.67–8.81). This was approximately 3.1 times lower than in Luhansk (21.92 per 100 000 population; 95% CI: 17.38–27.28).

Conclusion: The results of this study show diverse CLL incidence and prevalence patterns in the adult population of the Russian Federation and Ukraine. Authors propose a more comprehensive study with large region involvement to provide a more precise description of the incidence and prevalence of CLL in Eastern European countries and to better understand disparities reported versus the USA and other Western countries.

Keywords:

• Chronic lymphocytic leukemia
• CLL
• Epidemiology
• Incidence
• Prevalence
• Russia
• Ukraine

Disclaimer statement

Contributors All authors took an active role in this study. Authors participated in critical revisions of the manuscript and have approved the article for publication. The authors contributed to the manuscript review, applying their clinical, epidemiology, and study design expertise.

Funding This study was sponsored and funded by GlaxoSmithKline.

Conflicts of interest The authors A.V., J.M., A.M., and C.M. are employed by GlaxoSmithKline. A.V. and C.M. own shares in GlaxoSmithKline. E.P. and M.H.S.P. are former employees of GlaxoSmithKline and E.P. is now employed by Novartis Pharmaceuticals, he also owns shares in Novartis Pharmaceuticals. A.L., V.M., and B.R. received investigator grants from GlaxoSmithKline for their involvement in the study.

Ethics approval None.

Acknowledgments

We thank all investigators for their contribution to the study. Ofatumumab is an asset of Novartis AG as of 2 March 2015. The sponsor was involved in the study design, collection, analysis, and interpretation of the data, in the writing of the report and in the decision to submit the article for publication.